Arbutus Biopharma Corporation Common Stock (ABUS)
Stock · NASDAQ · Health Care
$4.23as of 10/16/2026
Price chart
Active signals
ABUS Signal Track Record
How signals performed across all stocks →What ABUS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -2.3% | 42% | September 18, 2026 |
| Bollinger Band Breakout | 25 | -2.5% | 24% | August 18, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -2.4% | 47% | October 1, 2026 |
| Bollinger Band Breakdown | 15 | +0.6% | 53% | October 7, 2026 |
| Any 20-session window (baseline) | 0.0% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ABUS
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 19
- Website
- www.arbutusbio.com/
Fundamentals
- 1-day range
- $4.18$4.29
- Market cap
- $896.82M
- P/E (trailing)
- 5.55
- P/E (forward)
- -25.53
- EPS (trailing)
- $0.78
- Dividend yield
- —
- Beta
- 0.79
- Avg. volume
- 4.81M
How Arbutus Biopharma Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Arbutus Biopharma Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- ABUSArbutus Biopharma Corporation Common Stock$4.22▼ 1.63%Market cap $896.82MP/E 5.55$3.5$5.45
- ANNXAnnexon Inc. Common Stock$3.41▼ 5.28%Market cap $917.52MP/E —$2.54$7.18
- AMPHAmphastar Pharmaceuticals Inc. Common Stock$25.87▼ 2.08%Market cap $873.48MP/E 14.15$16.65$29.52
- DSGNDesign Therapeutics Inc. Common Stock$10.31▼ 1.62%Market cap $861.75MP/E —$5.28$17.25
- ACRSAclaris Therapeutics Inc. Common Stock$3.28▼ 6.02%Market cap $850.55MP/E —$1.74$6.6
- COLLCollegium Pharmaceutical Inc. Common Stock$23.19▲ 0.04%Market cap $944.15MP/E 15.18$21.43$50.79
- OMEROmeros Corporation Common Stock$16.2▼ 13.78%Market cap $951.74MP/E 10.87$4.06$21.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ABUS Arbutus Biopharma Corporation Common Stock | $896.82M | 5.55 | $4.22 | ▼ 1.63% | $3.5$5.45 |
| ANNX Annexon Inc. Common Stock | $917.52M | — | $3.41 | ▼ 5.28% | $2.54$7.18 |
| AMPH Amphastar Pharmaceuticals Inc. Common Stock | $873.48M | 14.15 | $25.87 | ▼ 2.08% | $16.65$29.52 |
| DSGN Design Therapeutics Inc. Common Stock | $861.75M | — | $10.31 | ▼ 1.62% | $5.28$17.25 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $850.55M | — | $3.28 | ▼ 6.02% | $1.74$6.6 |
| COLL Collegium Pharmaceutical Inc. Common Stock | $944.15M | 15.18 | $23.19 | ▲ 0.04% | $21.43$50.79 |
| OMER Omeros Corporation Common Stock | $951.74M | 10.87 | $16.2 | ▼ 13.78% | $4.06$21.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV CureSeekingAlpha · 10/8/2026
- Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender OfferYahoo · 10/1/2026
- Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender OfferYahoo · 9/30/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 9/25/2026
- Roivant Sciences: Diverse Exposure To Biotech Niches Through VantsSeekingAlpha · 9/13/2026
Insider Activity
Insider Actions →- Tuan Nguyen · October 1, 2026 · Disposition48.1K @ $5
- Sawhney Roger · October 1, 2026 · Disposition17.1K @ $5
- Lindsay Androski · October 1, 2026 · Disposition24.7K @ $5
- Beardsley Robert A · October 1, 2026 · Disposition17.9K @ $5
- Lindsay Androski · September 18, 2026 · Option Exercise10.5K @ $4.39
- Lindsay Androski · September 18, 2026 · Option Exercise116.4K @ $3.2
- Lindsay Androski · September 18, 2026 · Tax Withholding82.5K @ $5.07
- Tuan Nguyen · September 18, 2026 · Option Exercise27.5K @ $4.39
- Tuan Nguyen · September 18, 2026 · Option Exercise265.6K @ $3.49
- Tuan Nguyen · September 18, 2026 · Tax Withholding206.6K @ $5.07
- Sawhney Roger · September 18, 2026 · Option Exercise78.8K @ $4.24
- Sawhney Roger · September 18, 2026 · Option Exercise52.5K @ $3.34
- Sawhney Roger · September 18, 2026 · Tax Withholding100.5K @ $5.07
- Beardsley Robert A · September 18, 2026 · Option Exercise78.8K @ $4.24
- Beardsley Robert A · September 18, 2026 · Option Exercise52.5K @ $3.2
Institutional Ownership
March 31, 2026
- Total shares held
- 137.23M
- Total value held
- $616.65M
- Institutional holders
- 163
- Unknown25.89M
- Unknown18.56M
- Unknown14.93M
- Unknown12.97M
- Unknown6.69M
- Unknown6.63M
- Unknown6.34M
- Unknown4.32M
- Unknown3.77M
- Unknown3.13M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
ABUS Featured in Whale Alert List of 10 Health Care Stocks
Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.
ABUS Featured in Whale Alert List of 10 Health Care Stocks. Arbutus Biopharma (ABUS) was named in a Benzinga article that highlighted 10 health care stocks receiving whale alerts during the day. The mention suggests that large institutional traders have placed sizable orders in ABUS. The stock is currently near its $4.26 support level, with an RSI of 40.4 and recent volume spikes. This activity may signal increased market interest in ABUS.